Mesoblast Limited (OTCMKTS:MEOBF – Get Free Report) was up 40.7% on Monday . The company traded as high as $1.90 and last traded at $1.90. Approximately 1,000 shares traded hands during trading, a decline of 99% from the average daily volume of 71,497 shares. The stock had previously closed at $1.35.
Mesoblast Stock Performance
The firm has a fifty day moving average of $1.45 and a 200 day moving average of $1.39.
About Mesoblast
Mesoblast Limited (OTCMKTS:MEOBF) is a global leader in regenerative medicine focused on the development and commercialization of innovative allogeneic cell therapies. The company’s proprietary platform harnesses mesenchymal lineage adult stem cells to address a range of inflammatory and immunological conditions. Mesoblast’s pipeline includes multiple late-stage and marketed products that target serious diseases with high unmet medical needs.
The company’s lead product, remestemcel-L (Ryvicor/Ryoncil), is under development for the treatment of steroid-refractory acute graft versus host disease in pediatric patients and has received conditional approval for certain indications in Japan.
See Also
- Five stocks we like better than Mesoblast
- How a Family Trust May Be Able To Help Preserve Your Wealth
- GOLD ALERT
- Once-in-a-generation financial shift is underway
- Wall Street Stockpicker Names #1 Stock of 2026
- Forget Amazon’s 1997 IPO… This Could Be 287 Times Bigger
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.
